$0.11 +0.00 (4.11%)
Japer Therapeutics, Inc. Warrants (JSPRW)
Company News
Deadline Alert: Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Jasper Therapeutics faces a class action lawsuit alleging securities fraud after revealing issues with a drug product lot that impacted clinical trial results, leading to study halts and significant stock price decline.
Jasper Reports Wider Loss in Fiscal Q2
Jasper Therapeutics reported a net loss of $1.74 per share in Q2 2025, with no revenue generated. The company is focusing exclusively on briquilimab, a monoclonal antibody for mast cell-driven diseases, while implementing significant cost-cutting measures.